eligibility_summary
Eligible: CD20+ LBCL (incl DLBCL, HGBCL, PMBCL, transformed FL), Part 1 R/R, CAR‑T eligible needing bridging, Part 2 non‑CMR 1 mo post‑CAR‑T or progressed, ECOG 0–1 (P1) or 0–2 (P2), adequate organ/hematologic function, negative HBV/HCV/HIV/COVID‑19. Exclude: active infection, CNS lymphoma, other invasive cancer <2 y, major cardiac/autoimmune dz, recent anticancer therapy, prior transplant (organ/allo, auto <100 d), steroids >25 mg/d, recent immunosuppression/live vaccine, severe mAb/CHO allergy, HLH.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 single‑arm trial in relapsed/refractory large B‑cell lymphoma evaluates a peri‑CAR‑T regimen of: 1) Glofitamab (Columvi) – a T‑cell–engaging bispecific monoclonal antibody (2:1 CD20:CD3) that binds CD20 on B cells and CD3 on T cells to activate cytotoxic T‑cell killing of malignant B cells, 2) Polatuzumab vedotin (Polivy) – an anti‑CD79b antibody‑drug conjugate delivering MMAE (microtubule inhibitor) to CD79b+ B cells, causing mitotic arrest and apoptosis, 3) Obinutuzumab (Gazyvaro) – a glycoengineered type II anti‑CD20 monoclonal antibody that enhances ADCC/ADCP and direct B‑cell death, given pre‑glofitamab to debulk/mitigate CRS. Targets/pathways: CD20+ and CD79b+ malignant B cells, T‑cell activation via CD3, BCR complex (CD79b), and microtubule disruption. Used as bridging to CAR‑T and after CAR‑T failure.